Other > Journal Blog
Lancet Global Health. 2017 November 10
Fotheringham C
Lancet Global Health. 2017 November 10
Journal Article > EditorialFull Text
BMJ. 2021 December 20; Volume 375; n3126.; DOI:10.1136/bmj.n3126
Caluwaerts S
BMJ. 2021 December 20; Volume 375; n3126.; DOI:10.1136/bmj.n3126
Journal Article > CommentaryFull Text
BJOG. 2013 June 11; Volume 120 (Issue 8); DOI:10.1111/1471-0528.12131
Garry RF
BJOG. 2013 June 11; Volume 120 (Issue 8); DOI:10.1111/1471-0528.12131
Journal Article > ResearchFull Text
BMC Pregnancy Childbirth. 2020 November 1; DOI:10.21203/rs.3.rs-62820/v1
Schuurmans J, Borgundvaag E, Finaldi P, Senat-Delva R, Desauguste F, et al.
BMC Pregnancy Childbirth. 2020 November 1; DOI:10.21203/rs.3.rs-62820/v1
The prevalence of (pre-)eclampsia in pregnant women in Haiti is high and access to maternal health services is scarce. Limited evidence exists around negative maternal and neonatal outcomes in Haitian women and their offspring. We describe the patient profile of women admitted to an obstetric emergency hospital in Port-au-Prince between January 2013 and June 2018 and the estimated risk factors for maternal death, stillbirth and low birthweight (LBW).
Methods
We calculated frequencies of age groups, singleton vs. multiple pregnancies, delivery procedures and antenatal care (ANC) services for all maternal admissions. We estimated the associated risk between these factors and the three negative outcomes by calculating odds ratios (OR) and their 95% confidence intervals (CI) using univariate and multivariate logistic regression. We adjusted for an interaction between delivery procedure and pregnancy category in the regression models for maternal death and stillbirth.
Results
We included 31,509 women and 24,983 deliveries and documented 204 (0.6%) maternal deaths (648/100,000 women giving birth), 1,962 (7.9%) stillbirths and 11,008 (44.1%) LBW neonates. 34.9% of all admissions (n = 10,991) were women with (pre-)eclampsia. Maternal death was more likely in women with complicated pregnancies and/or deliveries and women with (pre-)eclampsia when undergoing a C-section compared to women with uncomplicated vaginal deliveries (OR 4.8; CI 1.7–13.8 and OR 2.3; CI 1.5–3.6 respectively). Stillbirth was more likely in women ≥ 35 years compared to women 20–34 years in complicated pregnancies and/or deliveries (OR 1.3; CI 1.1–1.6) and (pre-)eclampsia (OR 1.4; CI 1.2–1.7). C-sections in women with a complicated pregnancy and/or delivery and women with (pre-)eclampsia reduced the risk of stillbirth (OR 0.7; CI 0.6–0.9 and OR 0.3; CI 0.2–0.3 respectively). Not attending ANC was associated with a higher risk of stillbirth (OR 4.8; CI 3.6–6.6) and LBW (OR 1.4; CI 1.1–1.9) for women with complicated pregnancies and/or deliveries.
Conclusion
Maternal mortality in high-risk pregnancies in CRUO is higher than the national estimate of 529 per 100,000 deliveries. Attendance of ANC services is associated with a decrease in adverse neonatal outcomes including LBW and stillbirth. We recommend that access to maternal and neonatal healthcare facilities in Port-au-Prince is improved.
Journal Article > ResearchAbstract
Sex Transm Dis. 2012 September 1 (Issue 9)
Danna LH, Korosteleva O, Warner L, Douglas J, Paul S, et al.
Sex Transm Dis. 2012 September 1 (Issue 9)
Incorrect condom use is a common problem that can undermine their prevention impact. We assessed the prevalence of 2 condom use problems, breakage/slippage and partial use, compared problems by partnership type, and examined associations with respondent, partner, and partnership characteristics.
Journal Article > ReviewAbstract
J Acquir Immune Defic Syndr. 2019 January 25; Volume 80 (Issue 5); DOI:10.1097/QAI.0000000000001957
O'Brien DP, Ford NP, Djirmay AG, Calmy A, Victoria M, et al.
J Acquir Immune Defic Syndr. 2019 January 25; Volume 80 (Issue 5); DOI:10.1097/QAI.0000000000001957
Evidence suggests that there are important interactions between HIV and Female Genital Schistosomiasis (FGS) that may have significant effects on individual and population health. However, the exact way they interact and the health impacts of the interactions are not well understood. In this paper we discuss what is known about the interactions between FGS and HIV, and the potential impact of the interactions. This includes the likelihood that FGS is an important health problem for HIV positive women in schistosoma-endemic areas potentially associated with an increased risk of mortality, cancer and infertility. Additionally, it may be significantly impacting the HIV epidemic in sub-Saharan Africa by making young women more susceptible to HIV. We call for immediate action and argue that research is urgently required to address these knowledge gaps and propose a research agenda to achieve this.
Conference Material > Video (talk)
Burtscher D
MSF Scientific Days International 2022. 2022 June 7; DOI:10.57740/77v0-d127
Conference Material > Poster
Gutierrez Popoca M, Tancred T
MSF Paediatric Days 2024. 2024 May 3; DOI:10.57740/C0eEY7Ha
Conference Material > Video (talk)
Rossi G
MSF Paediatric Days 2022. 2022 November 29; DOI:10.57740/mgyf-jv27
English
Français
Conference Material > Abstract
Nesbitt RC
Epicentre Scientific Day Paris 2023. 2023 June 8
BACKGROUND
Hepatitis E causes high mortality among pregnant women with case fatality risks of 10-25%, and adverse fetal outcomes. Hecolin® is a safe and efficacious vaccine against Hepatitis E, but there is an evidence gap on its safety in pregnant women. In 2015 the WHO recommended its use in response to outbreaks, including vaccinating pregnant women. The first mass reactive vaccination campaign against Hepatitis E was conducted in Bentiu including pregnant women and achieved high administrative vaccination coverage. We aimed to document pregnancy outcomes in a cohort of vaccinated and non-vaccinated pregnant women.
METHODS
An exhaustive pregnancy census was conducted after the second vaccination round from 16 May to 30 June 2022 to recruit women who were pregnant between 1 January 2022 and the interview date. Women were recontacted a minimum of 28 days after expected delivery to assess pregnancy outcome. Categorization of the cohort according to timing of potential vaccine exposure in pregnancy and regression models to evaluate the association between at least one dose in pregnancy and pregnancy outcomes is ongoing.
RESULTS
Of 20,674 women of childbearing age who consented for interview, 3,458 (16.7%) reported being pregnant since 1 January 2022. Women were a mean of 25.5 years old, had a median of 2 previous pregnancies (0-11), and 21 (0.6%) reported experiencing jaundice during their current pregnancy. Overall, 2723 (78.7%) women received at least one dose of Hecolin®. Access to delivery care was high, with 90% of women delivering in a health facility; 357 (10.3%) women reported a complication during delivery and 16 (0.5%) reported a caesarean section. According to interview, 3233 (93.5%) women had a livebirth, and 225 (6.9%) had a pregnancy loss, including 57 (1.6%) reported stillbirths, translating to a stillbirth rate of 17.6/1000 pregnancies, compared to the national estimate of 25.8/1000 pregnancies.
CONCLUSION
It was feasible to implement an observational study on the safety of vaccination in pregnancy alongside the first deployment of Hecolin® in a humanitarian emergency setting. Access to delivery care is reflected in the lower than national average rate of stillbirth in the camp. Results are expected to narrow the evidence gap on the safety of this vaccine in pregnancy.
KEY MESSAGE
A cohort study on the safety of vaccination in pregnancy was implemented alongside the first deployment of Hecolin® in a humanitarian emergency setting. Preliminary results show overall high coverage with at least one dose and access to delivery care among women in the cohort
This abstract is not to be quoted for publication.
Hepatitis E causes high mortality among pregnant women with case fatality risks of 10-25%, and adverse fetal outcomes. Hecolin® is a safe and efficacious vaccine against Hepatitis E, but there is an evidence gap on its safety in pregnant women. In 2015 the WHO recommended its use in response to outbreaks, including vaccinating pregnant women. The first mass reactive vaccination campaign against Hepatitis E was conducted in Bentiu including pregnant women and achieved high administrative vaccination coverage. We aimed to document pregnancy outcomes in a cohort of vaccinated and non-vaccinated pregnant women.
METHODS
An exhaustive pregnancy census was conducted after the second vaccination round from 16 May to 30 June 2022 to recruit women who were pregnant between 1 January 2022 and the interview date. Women were recontacted a minimum of 28 days after expected delivery to assess pregnancy outcome. Categorization of the cohort according to timing of potential vaccine exposure in pregnancy and regression models to evaluate the association between at least one dose in pregnancy and pregnancy outcomes is ongoing.
RESULTS
Of 20,674 women of childbearing age who consented for interview, 3,458 (16.7%) reported being pregnant since 1 January 2022. Women were a mean of 25.5 years old, had a median of 2 previous pregnancies (0-11), and 21 (0.6%) reported experiencing jaundice during their current pregnancy. Overall, 2723 (78.7%) women received at least one dose of Hecolin®. Access to delivery care was high, with 90% of women delivering in a health facility; 357 (10.3%) women reported a complication during delivery and 16 (0.5%) reported a caesarean section. According to interview, 3233 (93.5%) women had a livebirth, and 225 (6.9%) had a pregnancy loss, including 57 (1.6%) reported stillbirths, translating to a stillbirth rate of 17.6/1000 pregnancies, compared to the national estimate of 25.8/1000 pregnancies.
CONCLUSION
It was feasible to implement an observational study on the safety of vaccination in pregnancy alongside the first deployment of Hecolin® in a humanitarian emergency setting. Access to delivery care is reflected in the lower than national average rate of stillbirth in the camp. Results are expected to narrow the evidence gap on the safety of this vaccine in pregnancy.
KEY MESSAGE
A cohort study on the safety of vaccination in pregnancy was implemented alongside the first deployment of Hecolin® in a humanitarian emergency setting. Preliminary results show overall high coverage with at least one dose and access to delivery care among women in the cohort
This abstract is not to be quoted for publication.